International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

BIOMAP Collaboration Update A Systemic Review on Biomarkers
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.

WHAT IS BIOMAP?

Atopic Dermatitis and Psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time, and response to treatment. BIOMAP will examine the causes and mechanisms of Atopic Dermatitis and Psoriasis to enable optimal treatments and an individualized therapy scheme for each patient. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm from reactive to proactive strategies encompassing disease biology and lifetime trajectory, matching the intervention with endotypes. Learn more about BIOMAP.

TWO NEW LAY SUMMARIES PUBLISHED

Summary 1: The Search for Measurable Predictors Linked with Negative Health Complications in Psoriasis

181 studies were identified investigating biomarkers linked with more extensive psoriasis and/or other linked health conditions such as joint disease. 22 promising biomarkers were selected from included studies, although none were supported by sufficient evidence to be used in current practice without further investigation. Several common limitations of approaches to investigate this important question were highlighted following a detailed evaluation of studies.

Findings can help focus future research efforts to facilitate promising biomarkers being used in clinical practice.

Read the complete publication: Biomarkers of Disease Progression in People with Psoriasis: A Scoping Review

BIOMAP Collaboration Graphic 1

Summary 2: The Search for Measurable Predictors Linked with Safe and Effective Response Treatment in Psoriasis

71 studies were identified investigating biomarkers linked with a less effective response or adverse events to tablet or injectable treatments used for psoriasis. Seven promising genetic biomarkers were identified following a detailed evaluation of the higher-quality studies. These biomarkers were found to play key roles in molecular pathways implicated in psoriasis. Findings from this study can help researchers prioritize biomarkers for future focused investigation to confirm their usefulness in clinical practice.

Read the full publication: Biomarkers of Systemic Treatment Response in People with Psoriasis: A Scoping Review

BIOMAP Collaboration Graphic 2

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

New IPC Guidelines on Generalized Pustular Psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Also Read

Generalized Pustular Psoriasis

New IPC Guidelines on Generalized Pustular Psoriasis

Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the essential features, the importance of accurate diagnosis, and the expected global impact on patient care.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.